Although the rate of pulmonary exacerbations requiring IV antibiotics has significantly decreased with the use of CFTR modulators, people with CF (PwCF) who are ineligible to take modulators continue to have infections that lead to pulmonary exacerbations. Here, CFTR is linked to cystic fibrosis.